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The Journal of Thoracic and Cardiovabjectives: Pulsatile blood flow has been regarded to be of importance for the
egulation of endocrine organs. A new generation of continuous flow mechanical
lood pumps is now available for clinical application. Patients with implanted
icroMed-DeBakey axial pumps show nonphysiologic low-pulsatile blood flow
rofiles, and therefore it appeared to be of interest to evaluate their possible effect
n the endocrine system.
ethods: Eight male patients and 1 female patients (mean age, 51  10 years) with
nd-stage left-sided heart failure were implanted with a MicroMed-DeBakey axial
ump. After a mean period of 67 19 days, basal pituitary hormone concentrations
nd their responses to a bolus injection of hypothalamic releasing hormones were
ested. In addition, thyroid hormones, testosterone, and plasma and urinary cate-
holamine levels were measured at baseline.
esults: Administration of the hypothalamic releasing hormones revealed nor-
al responses of all pituitary hormones (adrenocorticotropic hormone, thyroid-
timulating hormone, luteinizing hormone, and prolactin), except for growth hor-
one, the response of which was slightly impaired (10.2  6.8 vs 19.9  6.5 ng/L,
 .05). Also, the cortisol response to the corticotropin-releasing hormone–
timulated adrenocorticotropic hormone release was normal, as were basal concen-
rations of thyroid hormones (triiodothyronine, thyroxine, free triiodothyronine, and
ree thyroxine), testosterone, and urinary catecholamines.
onclusions: Implantation of a continuous flow axial pump with low-pulsatile blood
ow profile appears to have no major effect on the hypothalamic-pituitary-endorgan
ystem and sympathoadrenal functions. This finding is reassuring for the growing
umber of patients treated with this convenient new pump and could contribute
onsiderably to their prognosis and quality of life.
atients with end-stage left-sided heart failure listed for cardiac transplantation
might deteriorate hemodynamically, despite maximal pharmacologic support.
In many cases bridge to transplantation with mechanical assist devices is the
nly option for these patients. Over the past 3 decades, mainly pulsatile blood
umps were used for clinical long-term support.1,2 Since November 1998, a new
eneration of miniaturized, implantable axial flow pumps is available for clinical
pplication.3,4 These pumps offer several advantages, such as small size, no noise,
scular Surgery ● January 2007
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CS
Pnd no need for a compliance chamber. However, patients
upported with implantable axial flow pumps demonstrate
onphysiologic, almost nonpulsatile blood flow patterns.
ver the centuries, it was believed that pulsatility of arterial
lood flow is essential for homeostasis in human subjects.
Disturbed neuroendocrine and sympathoadrenal function
aused by nonphysiologic organ perfusion could be ex-
ected to have a major effect on cardiovascular and mus-
ular function in patients with severe left-sided heart failure
nd thereby limit the beneficial hemodynamic effects of a
iniaturized implantable system. Indeed, several studies
ave suggested adrenocortical dysfunction during non-
ulsatile perfusion in human subjects.5 In contrast, early
xperiments with nonpulsatile blood pumps in animals pro-
ided evidence that this pathophysiologic state of nonpul-
atile or low-pulsatile blood flow can be tolerated for short-
erm support, despite alterations in the microcirculation.6
Because the effect of long-term low pulsatility on the
ndocrine system is not known, we performed pituitary
land multifunction tests in patients implanted with a con-
inuous MicroMed–DeBakey axial flow pump and evalu-
ted their pituitary and associated endocrine functions, as
ell as their sympathoadrenal states.
ethods
rom September 2000 through February 2002, 9 patients (8 men
nd 1 woman; mean age, 51  10 years; age range, 36-64 years)
ith end-stage left-sided heart failure were implanted with a
ontinuous MicroMed–DeBakey axial flow pump as a bridge to
ransplantation. Despite maximal pharmacologic support with ino-
ropic therapy, vasodilator therapy, or both, patients showed signs
f acute hemodynamic deterioration and end-organ dysfunction at
he time of implantation. In 4 patients the underlying disease was
schemic cardiomyopathy, and 5 patients had dilated cardiomyop-
thy. Patients recovered completely after implantation of the ven-
ricular assist device (VAD) and were started on a regular physical
raining program to overcome long-term immobilization preoper-
tively. The early postoperative period was characterized by com-
lete nonpulsatile arterial flow patterns. Partial recovery of the
atural left ventricle added a certain degree of pulsatility not
xceeding pulse pressures greater than 10 mm Hg. Because our
trategy in those patients supported with left VADs was to main-
ain high pump support for maximal exercise capacity, all patients
Abbreviations and Acronyms
ACTH adrenocorticotropic hormone
CRH  corticotropin-releasing hormone
GH  growth hormone
LH  luteinizing hormone
T3  triiodothyronine
T4  thyroxine
TSH  thyroid-stimulating hormoneresented high pump flows in the average range between 4.5 and a
The Journal of ThoraL/min with the aortic valve closed over the whole pumping
eriod. End-organ function normalized, and postoperative pharma-
ologic therapy consisted of angiotensin-converting enzyme inhib-
tor treatment with 40 mg/d lisinopril, anticoagulation with phen-
rocoumon (international normalize ratio target levels of 2.5-3.5),
nd antiaggregation with 100 mg of salicylic acid and 225 mg of
ipyridamol. Endocrine testing was performed after full rehabili-
ation of the patients after a mean pumping period of 67 19 days.
he control group consisted of 10 healthy men matched for age
nd weight. The protocol was approved by the institutional ethics
ommittee.
All tests were performed at 10 AM, and all subjects were starved
or at least 8 hours. Patients were tested for basal serum hormone
oncentrations and anterior pituitary hormone response to bolus
njection of hypothalamic releasing hormones (corticotropin-
eleasing hormone [CRH], 100 g: Ferring, Kiel, Germany;
hyreotropin-releasing hormone, 200 g: Aventis Pharma, Frank-
urt, Germany; growth hormone [GH]–releasing hormone, 100
g: Ferring; luteinizing hormone–releasing hormone, 100 g,
ventis Pharma). Blood samples were assayed for adrenocor-
icotropic hormone (ACTH), cortisol, thyroid-stimulating hor-
one (TSH), luteinizing hormone (LH), GH, and prolactin at
ultiple time points (15, 0, 15, 30, 60, 90, and 120 minutes). In
ddition, we measured basal serum concentrations of thyroid hor-
ones, testosterone, the binding proteins thyroxin-binding globu-
in and sex hormone–binding globulin, and plasma and urinary
atecholamines (epinephrine, norepinephrine, and dopamine).
lood for determination of plasma ACTH concentrations was
rawn in prechilled ethylenediamine tetraacetic acid tubes that
ere immediately centrifuged and stored at 20°C until assayed
ith a commercially available radioimmunoassay. GH, cortisol,
nd sexual hormone–binding globulin levels were measured with
ommercially available radioimmunoassays. Serum concentrations
f triiodothyronine (T3), thyroxine (T4), free T3, free T4, testos-
erone, TSH, LH, and prolactin were measured by using electro-
hemiluminescence (ELECSYS, Roche Diagnostics GmbH,
annheim, Germany). Epinephrine, norepinephrine, and dopa-
ine excretion in 24-hour urinary samples was analyzed by using
igh-performance liquid chromatography.
Data are expressed as medians and standard errors of the mean. To
nalyze individual serial measurements of ACTH, cortisol, TSH, LH,
H, and prolactin, we calculated the area under the curve according
o the trapezoid rule7 divided by the elapsed time interval. Further
aximum increase of ACTH, cortisol, TSH, LH, GH, and prolactin
as calculated for each patient. The Mann–Whitney U test was used
o compare groups of continuous data. All data were computed with
icrosoft Excel for Windows, version 6.0 (Microsoft, Redmond,
ash) and SPSS for windows (SPSS, Chicago, Illinois).
esults
dministration of a bolus injection of maximally effective
oses of hypothalamic releasing hormones resulted in a
rompt increase of ACTH, TSH, LH, GH, and prolactin
erum concentrations in all subjects. Peak levels of pituitary
ormones were reached in both groups 30 minutes after
timulation, except for prolactin, for which peak levels were
ttained 15 minutes after thyreotropin-releasing hormone
cic and Cardiovascular Surgery ● Volume 133, Number 1 3
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CSP
dministration. There was no significant difference between
he 2 study groups as to plasma/serum concentrations of
CTH (48.2  12.4 vs 46.3  9.9 pg/mL), TSH (19.5 
0.7 vs 15.38  1.65 mU/L [TSH  U/mL]), LH (22.9 
.8 vs 26.3  5.9 U/L), and prolactin (91.6  47.7 vs 96.6
14.4 g/L [ng/mL]) at 30 minutes after stimulation and
rolactin (95.5  45.3 vs 111.5  16.5 g/L [ng/mL]) 15
inutes after stimulation (Figure 1). Also, the adrenocorti-
al (ie, cortisol) response to a normal ACTH increase after
RH stimulation was comparable between study patients
nd healthy control subjects (Figure 1). In every patient the
aximum increase of cortisol (peak concentration minus
asal concentration) was 7 g/dL or more, which is con-
ACTH
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Figure 1. Adrenocorticotropic hormone (ACTH ; in pi
deciliter) responses after 100 g corticotropin-releasin
in milliunits per liter [TSH  U/mL]) and prolactin re
shown. Growth hormone (GH ; in nanograms per mil
hormone and luteinizing hormone (LH ; in units per li
hormone are shown. Patients receiving a left ventricul
and control subjects are indicated by filled bars. 1, Zer
minutes; and 6, 120 minutes.idered the cutoff point for normal adrenocortical function. n
The Journal of Thoracic and Cardiovascular Surgery ● Januarn contrast, mean GH response to a supramaximal dose of
he hypothalamic releasing peptide GH-releasing hormone
as slightly diminished (10.2  6.8 vs 19.9  6.5 g/L, P
.05). However, all patients had a GH response of greater
han 3 g/L, which is considered the cutoff point for diag-
osis of severe GH deficiency.
Peripheral thyroid hormones and sex steroids (T4, T3,
ree T4, free T3, and testosterone) and their binding proteins
thyroxin-binding globulin and sexual hormone–binding
lobulin) were found to be within the normal range. Fur-
hermore, urinary excretion of epinephrine (5.3 2.0 g/24
ours), norepinephrine (60.8  15.8 g/24 hours), and
opamine (419.8 121.3 g/24 hours) did not deviate from
Cortisol
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ams per milliliter) and cortisol (in micrograms per
rmone are shown. Thyroid-stimulating hormone (TSH ;
ses to 200 g of thyreotropin-releasing hormone are
) response to 100 g of growth hormone–releasing
esponse to 100 g of luteinizing hormone–releasing
sist device (LVAD) are indicated by shaded gray bars,
nutes; 2, 15 minutes; 3, 30 minutes; 4, 60 minutes; 5, 90cogr
g ho
spon
liliter
ter) r
ar as
o miormal in this cohort (Table 1).
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Piscussion
t was believed for decades that pulsatility of arterial blood
ow is essential for homeostasis in human subjects and that
ubstantial changes in pulse pressure would cause critical
isorders in many sensitive regulation systems of the human
ody. Therefore pulsatile pump mode for prolonged me-
hanical circulatory support was assumed to be superior to
he nonphysiologic pulseless perfusion of continuous flow
otary blood pumps.
It has been shown recently, however, that maintenance of
ystemic circulation with implanted continuous axial flow
lood pumps for bridge to transplantation is feasible and
ell tolerated in patients for several months.3,4 Problems
xperienced in early animal experiments, such as increased
otal peripheral resistance, increased circulating blood vol-
me, reduced oncotic pressures, and low hematocrit values,6
ere not seen in these first patients with implanted axial
ow pumps. It is known that essential organs of the body are
ble to autoregulate their perfusion pressures in a certain
ange to maintain an adequate blood flow to guarantee
egular metabolism and protect themselves from damage.
he brain, for instance, keeps cerebral blood flow constant
ver a range of approximately 60 to 150 mm Hg mean aortic
ressure. It has been observed, however, that cerebral blood
ow and cerebral metabolic rate for oxygen are reduced by
pproximately 30% during cardiopulmonary bypass surgery
hen a nonpulsatile pump flow mode is maintained.8 Fur-
hermore, it is known that patients with advanced chronic
eart failure present with endocrine dysregulations. In
hronic heart failure norepinephrine, epinephrine, cortisol,
rolactin, and human GH levels are increased, and thyroid
unction is impaired. Insulin-like growth factor I, testoster-
ABLE 1. Baseline concentrations of hormones and sexual
ormone binding globulin
Patients with
LVADs Normal range
rinary epinephrine excretion
(24 h)
5.3  2.0 20 g/24 hours
rinary norepinephrine
excretion (24 h)
60.8 15.8 23-105 g/24 h
rinary dopamine excretion
(24 h)
419 123 190-450 g/24 h
SH 2.0 1.3 4 U/L
hyroxine 90 15 50-120
riiodothyronine 1.4 0.2 0.6-2.0
exual hormone–binding
globulin
72.8 11.7 16-76 nmol/L
estosterone 5.7 1.3 2.7-10.7 ng/mL
GF-I 205.7 91 105-330 ng/mL
VADs, Left ventricular assist devices; TSH, thyroid-stimulating hormone;
GF-I, insulin-like growth factor I.ne, and estrogen levels appear to be normal.9-11 This study h
The Journal of Thoraemonstrates that adenohypophyseal function in response to
timulation by hypothalamic releasing hormones is main-
ained in patients, except for GH, the response of which was
iminished. It should be stressed, however, that no single
atient exhibited severe GH deficiency, defined as a maxi-
al GH concentration of 3 g/L or less at the Port Stephens
onsensus Conference.12 Because of the positive inotropic
ffects of GH, the finding of only mild impairment of
omatotropic function appears to be relevant in patients with
eart failure.13,14 Normal or only slightly impaired GH
oncentrations also facilitate physical training15 and reha-
ilitation of these patients, which must be considered of
reat importance for further prognosis and outcome after
eart transplantation.
Furthermore, hypothalamic-pituitary-adrenocortical func-
ion was not impaired in our patients with implanted devices,
s evidenced by a normal cortisol response to a normal ACTH
ncrease after administration of a maximally effective dose
f CRH. The criteria for intact adrenal function include the
ttainment of a maximal plasma cortisol concentration of at
east 18 g/dL, a cortisol increment of at least 7 g/dL
reater than the basal value, or both. This finding is not only
emarkable in view of the nonpulsatile blood flow but also
oints toward a well-adapted general health condition of
atients with MicroMed–DeBakey axial flow pumps im-
lanted for a mean time of 67  19 days. Chronic stress as
consequence of a severely impaired general health status
ould have lead to increased cortisol concentrations and
eranged hypothalamic-pituitary feedback, with deleterious
ffects on cardiovascular, metabolic, and immune func-
ions.16-18 Furthermore, this observation is in agreement
ith previous studies during and after cardiopulmonary
ypass surgery using pulsatile and nonpulsatile perfu-
ion.19,20 In contrast, several earlier studies had suggested
hat nonpulsatile blood flow during cardiopulmonary sur-
ery decreases plasma cortisol levels,5 which also might be
xpected to compromise cardiovascular function caused by
mpairment of fluid and mineral homeostasis and the loss of
he permissive effects of glucocorticoids for catecholamines
n peripheral blood vessels. Because our investigations
ere performed about 70 days after implantation of the
icroMed–DeBakey VAD, we cannot rule out that the
atients might have adapted themselves to the nearly
onpulsatile flow pattern. Tsutsui and Nose21 report in
arly animal experiments with complete nonpulsatile
ow that idioperipheral pulsations could be observed.
hey suggested that the animals were able to add pulsa-
ile components of their own, allowing them to maintain
ufficient circulation. From our patients with implanted
ontinuous blood pumps, we learned that pulsatility of
lood flow occurs as soon as contractility of the natural
eart recovers.3,4
cic and Cardiovascular Surgery ● Volume 133, Number 1 5
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CSPWhereas high catecholamine levels have been described
n patients with cardiomyopathy and immediately after im-
lantation of mechanical assist devices,22,23 we found nor-
al plasma catecholamine concentrations and urinary cate-
holamine excretion. This further suggests good physical
daptation of our patients maintained several weeks after
mplantation of the DeBakey VAD.
No changes versus those seen in healthy subjects were
een as to thyroid hormone concentrations. This is in con-
rast to a study by Buket and colleagues,24 in which non-
ulsatile flow has been shown to affect thyroid hormone
evels. In this study both pulsatile and even more nonpul-
atile flow decreased free T3 levels but not TSH, T4, and
ree T4 levels. Such low T3 syndrome was observed within
4 hours after cardiopulmonary bypass surgery and is re-
ated to the severe medical condition of these patients rather
han to the choice of cardiac assist device.25 The normal
hyroid function test results again document the good phys-
cal condition of our patients and their adaptation to the
onpulsatile blood flow pump 70 days after implantation of
he assist device.
In conclusion, this study demonstrates an almost normal
ndocrine regulation in patients receiving a continuous
icroMed–DeBakey axial flow pump. This proves that
rolonged support with a nonpulsatile mechanical assist
evice is well tolerated by endocrine organs, which play a
ajor role in the maintenance of homeostasis in human
ubjects. In addition, this finding documents the good long-
erm adaptation of these patients, which could have a major
ffect on their prognosis and quality of life.
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